UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Take your PIK: phosphatidylinositol 3-kinase inhibitors race through the clinic and toward cancer therapy

Molecular cancer therapeutics, 2009-01, Vol.8 (1), p.1-9

2009

Volltextzugriff (PDF)

Effect of KRAS Oncogene Substitutions on Protein Behavior: Implications for Signaling and Clinical Outcome

JNCI : Journal of the National Cancer Institute, 2012-02, Vol.104 (3), p.228-239

2012

Volltextzugriff (PDF)

Mutations in the Phosphatidylinositol-3-Kinase Pathway Predict for Antitumor Activity of the Inhibitor PX-866 whereas Oncogenic Ras Is a Dominant Predictor for Resistance

Cancer research (Chicago, Ill.), 2009-01, Vol.69 (1), p.143-150

2009

Volltextzugriff (PDF)

An Inhibitor of the Pleckstrin Homology Domain of CNK1 Selectively Blocks the Growth of Mutant KRAS Cells and Tumors

Cancer research (Chicago, Ill.), 2019-06, Vol.79 (12), p.3100-3111

2019

Volltextzugriff (PDF)

Inhibitors of phosphatidylinositol-3-kinase in cancer therapy

Molecular aspects of medicine, 2010-04, Vol.31 (2), p.135-144

2010

Volltextzugriff (PDF)

Molecular pharmacology and antitumor activity of PX-866, a novel inhibitor of phosphoinositide-3-kinase signaling

Molecular cancer therapeutics, 2004-07, Vol.3 (7), p.763-772

2004

Volltextzugriff (PDF)

Outlier analysis of functional genomic profiles enriches for oncology targets and enables precision medicine

BMC genomics, 2016-06, Vol.17 (1), p.455-455, Article 455

2016

Volltextzugriff (PDF)

Stability of Phosphoprotein as a Biological Marker of Tumor Signaling

Clinical cancer research, 2005-06, Vol.11 (12), p.4338-4340

2005

Volltextzugriff (PDF)

The phosphatidylinositol-3-kinase inhibitor PX-866 overcomes resistance to the epidermal growth factor receptor inhibitor gefitinib in A-549 human non–small cell lung cancer xenografts

Molecular cancer therapeutics, 2005-09, Vol.4 (9), p.1349-1357

2005

Volltextzugriff (PDF)

Chemical Proteomics Identifies Druggable Vulnerabilities in a Genetically Defined Cancer

Cell, 2017-10, Vol.171 (3), p.696-709.e23

2017

Volltextzugriff (PDF)

The Pten-Parkin Axis: At the Nexus of Cancer and Neurodegeneration

Molecular cell, 2017-03, Vol.65 (6), p.959-960

2017

Volltextzugriff (PDF)

Peroxisome proliferator-activated receptor γ agonist pioglitazone prevents the hyperglycemia caused by phosphatidylinositol 3-kinase pathway inhibition by PX-866 without affecting antitumor activity

Molecular cancer therapeutics, 2009-01, Vol.8 (1), p.94-100

2009

Volltextzugriff (PDF)

Efficacy and Imaging-Enabled Pharmacodynamic Profiling of KRAS G12C Inhibitors in Xenograft and Genetically Engineered Mouse Models of Cancer

Molecular cancer therapeutics, 2023-07, Vol.22 (7), p.891-900

2023

Volltextzugriff (PDF)

Correction: An Inhibitor of the Pleckstrin Homology Domain of CNK1 Selectively Blocks the Growth of Mutant KRAS Cells and Tumors

Cancer research (Chicago, Ill.), 2019-10, Vol.79 (20), p.5457-5457

2019

Volltextzugriff (PDF)

The skin and hair as surrogate tissues for measuring the target effect of inhibitors of phosphoinositide-3-kinase signaling

Cancer chemotherapy and pharmacology, 2006-10, Vol.58 (4), p.444-450

2006

Volltextzugriff (PDF)

Inhibiting PI-3-K for glioma therapy

Cell cycle (Georgetown, Tex.), 2009-02, Vol.8 (3), p.335-337

2009

Volltextzugriff (PDF)

Take your PIK: PI-3-kinase inhibitors race through the clinic and towards cancer therapy

Molecular cancer therapeutics, 2009-01, Vol.8 (1), p.1-9

2009

Volltextzugriff (PDF)

The biological effects of isoform-specific PI3-kinase inhibition

Current opinion in drug discovery & development, 2010-01, Vol.13 (1), p.41

2010

Volltextzugriff (PDF)

Abstract 1842: PHT-782 an inhibitor of the KRAS signaling nanocluster protein CNKSR1 blocks mutant KRAS signaling and cell growth but does not inhibit wild type KRAS cell growth

Cancer research (Chicago, Ill.), 2012-04, Vol.72 (8_Supplement), p.1842-1842

2012

Volltextzugriff (PDF)

Abstract A197: Oncogenic KRAS is dependent on the scaffold protein CNKSR1 for cell growth and signaling

Molecular cancer therapeutics, 2011-11, Vol.10 (11_Supplement), p.A197-A197

2011

Volltextzugriff (PDF)

Abstract 3454: Establishing role of KRAS mutation on NSCLC radio-sensitivity

Cancer research (Chicago, Ill.), 2012-04, Vol.72 (8_Supplement), p.3454-3454

2012

Volltextzugriff (PDF)

Abstract 306: KRas mediated induction of HIF-1α in normoxia promotes tumorigenesis and identifies HIF-1α as a therapeutic target

Cancer research (Chicago, Ill.), 2010-04, Vol.70 (8_Supplement), p.306-306

2010

Volltextzugriff (PDF)

Checkpoint “Madness”

Cell cycle (Georgetown, Tex.), 2009-02, Vol.8 (3), p.335-337

2009

Volltextzugriff (PDF)

The PPARγ agonist pioglitazone prevents the hyperglycemia caused by phosphoinositide-3-kinase pathway inhibition by PX-866 without affecting antitumor activity

Molecular cancer therapeutics, 2009-01, Vol.8 (1), p.94-100

2009

Volltextzugriff (PDF)

The phosphoinositide-3-kinase inhibitor PX-866 overcomes resistance to the EGFR inhibitor gefitinib in A-549 human non small cell lung cancer xenografts

Molecular cancer therapeutics, 2005-09, Vol.4 (9), p.1349-1357

2005

Volltextzugriff (PDF)

1 – 25 von 59

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(54)
Mit Volltextzugriff
(54)

Publikationsform

Artikel
(58)
Dissertationen
(1)

Sprache

Englisch
(59)

Erscheinungsjahr

n.n

Thema

Science & Technology
(33)
Life Sciences & Biomedicine
(29)
Humans
(23)
Animals
(17)
Oncology
(16)
Biological And Medical Sciences
(12)
Medical Sciences
(12)
Mice
(12)
Chemistry
(11)
Cell Line, Tumor
(10)
Pharmacology. Drug Treatments
(10)
Physical Sciences
(10)
Pharmacology & Pharmacy
(9)
Chemistry, Organic
(8)
Phosphatidylinositol 3-Kinases - Antagonists & Inhibitors
(8)
Signal Transduction
(8)
Antineoplastic Agents - Pharmacology
(7)
Enzyme Inhibitors - Pharmacology
(7)
Mice, Scid
(7)
Phosphatidylinositol 3-Kinases - Metabolism
(7)

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Take your PIK: phosphatidylinositol 3-kinase inhibitors race through the clinic and toward cancer therapy

Effect of KRAS Oncogene Substitutions on Protein Behavior: Implications for Signaling and Clinical Outcome

Mutations in the Phosphatidylinositol-3-Kinase Pathway Predict for Antitumor Activity of the Inhibitor PX-866 whereas Oncogenic Ras Is a Dominant Predictor for Resistance

An Inhibitor of the Pleckstrin Homology Domain of CNK1 Selectively Blocks the Growth of Mutant KRAS Cells and Tumors

Inhibitors of phosphatidylinositol-3-kinase in cancer therapy

Molecular pharmacology and antitumor activity of PX-866, a novel inhibitor of phosphoinositide-3-kinase signaling

Outlier analysis of functional genomic profiles enriches for oncology targets and enables precision medicine

Stability of Phosphoprotein as a Biological Marker of Tumor Signaling

The phosphatidylinositol-3-kinase inhibitor PX-866 overcomes resistance to the epidermal growth factor receptor inhibitor gefitinib in A-549 human non–small cell lung cancer xenografts

Chemical Proteomics Identifies Druggable Vulnerabilities in a Genetically Defined Cancer

The Pten-Parkin Axis: At the Nexus of Cancer and Neurodegeneration

Peroxisome proliferator-activated receptor γ agonist pioglitazone prevents the hyperglycemia caused by phosphatidylinositol 3-kinase pathway inhibition by PX-866 without affecting antitumor activity

Efficacy and Imaging-Enabled Pharmacodynamic Profiling of KRAS G12C Inhibitors in Xenograft and Genetically Engineered Mouse Models of Cancer

Correction: An Inhibitor of the Pleckstrin Homology Domain of CNK1 Selectively Blocks the Growth of Mutant KRAS Cells and Tumors

The skin and hair as surrogate tissues for measuring the target effect of inhibitors of phosphoinositide-3-kinase signaling

Inhibiting PI-3-K for glioma therapy

Take your PIK: PI-3-kinase inhibitors race through the clinic and towards cancer therapy

The biological effects of isoform-specific PI3-kinase inhibition

Abstract 1842: PHT-782 an inhibitor of the KRAS signaling nanocluster protein CNKSR1 blocks mutant KRAS signaling and cell growth but does not inhibit wild type KRAS cell growth

Abstract A197: Oncogenic KRAS is dependent on the scaffold protein CNKSR1 for cell growth and signaling

Abstract 3454: Establishing role of KRAS mutation on NSCLC radio-sensitivity

Abstract 306: KRas mediated induction of HIF-1α in normoxia promotes tumorigenesis and identifies HIF-1α as a therapeutic target

Checkpoint “Madness”

The PPARγ agonist pioglitazone prevents the hyperglycemia caused by phosphoinositide-3-kinase pathway inhibition by PX-866 without affecting antitumor activity

The phosphoinositide-3-kinase inhibitor PX-866 overcomes resistance to the EGFR inhibitor gefitinib in A-549 human non small cell lung cancer xenografts

Suchergebnisse filtern